Palo Alto – October 13, 2020 – Cooley advised Pulmonx, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, on its $218.5 million initial public offering of 11,500,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Partners Mark Weeks and Seth Gottlieb led the Cooley team advising Pulmonx.

BofA Securities and Morgan Stanley acted as joint lead book-running managers for the offering. Stifel, Wells Fargo Securities and Canaccord Genuity acted as lead managers for the offering.

Pulmonx, whose securities now trade on the Nasdaq Global Select Market under the symbol “LUNG,” is focused on providing planning tools and treatments for obstructive lung disease. With the Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, its solution is designed to address the need for a more effective, minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.